News

An antibody test for the virus that causes COVID-19, developed by researchers at The University of Texas at Austin in collaboration with Houston Methodist and other institutions, is more accurate and can handle a much larger number of donor samples at lower overall cost than standard antibody tests currently in use. In the near term, the test can be used to accurately identify the best donors for convalescent plasma therapy and measure how well candidate vaccines and other therapies elicit an immune response.

When the novel coronavirus began spreading across the United States this spring, The University of Texas at Austin quickly purchased three state-of-the-art robots and assembled additional equipment capable of processing hundreds of COVID-19 test samples every day.

We asked you, dear listeners, to send us your most burning questions about COVID-19. And you didn't disappoint. You asked: When will it be safe for my 12-week-old baby to meet her grandparents? Can you catch it twice? Is the virus mutating and will that make it harder to develop vaccines? In today's episode, our three experts get to the bottom of these questions, and more.

Scientists at The University of Texas at Austin have discovered how some cells within a bacterial swarm will sacrifice themselves so that other cells in the swarm have a better chance of surviving onslaught by antibiotics, in a discovery important for efforts to address antibiotic resistance.

The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

Responding to a need to quickly develop billions of doses of lifesaving COVID-19 vaccines, a scientific team at The University of Texas at Austin has successfully redesigned a key protein from the coronavirus, and the modification could enable much faster and more stable production of vaccines worldwide.

When the first COVID-19 vaccine trial in the U.S. began on March 16, history was being made. Never before had a potential vaccine been developed and produced for human trials so quickly—just 66 days since scientists published the genome sequence of the virus that causes the disease. After news this week that Phase 1 of the vaccine's trial yielded promising results, the same candidate will enter the final phase of human trials later this month. This blindingly fast effort was only possible because a group of scientists and their partners in industry had already invested years in laying the groundwork.

The brain's primary immune cells play a fundamental role in alcohol use disorder, according to a new study from Scripps Research and The University of Texas at Austin. The scientists are the first to link these cells—known as microglia—to the molecular, cellular and behavioral changes that promote the increased drinking that's associated with alcohol dependence.

The novel coronavirus has been compared to the flu almost from the moment it emerged in late 2019. They share a variety of symptoms, and in many cases, an influenza test is part of the process for diagnosing COVID-19.

As terrifying as the current pandemic is, scientists believe some of the hundreds of other known coronaviruses in bats might also have the potential to make the cross-species leap into humans, as this one probably did. Scientists are already thinking about ways to prevent another coronavirus from spiraling out of control. Basic research published in the journal Science provides evidence that an antibody therapy that's effective against all SARS-like coronaviruses is possible.